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A B S T R A C T
Objectives: To evaluate healthcare providers’ (HCPs’) knowledge, attitudes and beliefs regarding
intrauterine contraception (IUC).
Study design: HCPs in eight European countries and Canada who saw at least 20 women per month for
contraception completed an online questionnaire. Responses were evaluated by country.
Results: In total, 1103 HCPs completed the survey: 633 obstetrician-gynecologists, 335 general
practitioners and 135 family planning clinicians (physician, midwife or nurse). When respondents in
different countries were asked to report their three main barriers to considering IUC, predominant
concerns were nulliparity (34–69%) and pelvic inﬂammatory disease (PID; 14–83%) for women in
general, and insertion difﬁculty (25–83%), PID (17–83%), insertion pain (7–60%) and infertility (6–55%)
for nulliparous women. In addition, 4–59% of HCPs reported that they never proactively include IUC in
contraceptive counseling for a nulliparous woman, regardless of her age. Furthermore, only 30–61% of
respondents correctly identiﬁed that, in the World Health Organization medical eligibility criteria for
IUC, nulliparity is category 2 (beneﬁts outweigh risks).
Conclusions: HCPs in Europe and Canada have clear gaps in their knowledge regarding IUC and misplaced
concerns persist, particularly regarding use of IUC in nulliparous women; the predominant
misconceptions are about PID, insertion difﬁculty and insertion pain. Further education on the evidence
is needed so that IUC is recognized as being suitable for young and nulliparous women and is included in
contraceptive counseling.
 2014 Published by Elsevier Ireland Ltd.
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Unintended pregnancy remains a global public health problem.
Worldwide, 41% of all pregnancies are unintended. However, the
percentages of pregnancies that are unintended vary geographi-
cally; 38%, 39%, 44%, 48% and 58% in Asia, Africa, Europe and North
America (US and Canada combined) and Latin America/Caribbean,
respectively. Within Europe, the percentages of pregnancies that
are unintended range from 39% in Southern Europe to 48% in
Eastern Europe [1]. Up to 50% of unintended pregnancies can
be attributed to contraceptive failure or non-compliance [2].* Corresponding author. Tel.: +49 40 7410 23801; fax: +49 40 7410 47283.
E-mail address: k.buehling@uke.de (K.J. Buhling).
http://dx.doi.org/10.1016/j.ejogrb.2014.10.020
0301-2115/ 2014 Published by Elsevier Ireland Ltd.Non-compliance is one of the major reasons for contraceptive
failure, particularly in adolescents. In addition, rates of unintended
pregnancy are highest among younger women [2]. Long-acting
reversible contraception (LARC), including intrauterine contracep-
tion (IUC), is highly effective and is not dependent on user
compliance [3].
The more widespread use of LARC might therefore be expected
to reduce unintended pregnancy rates. The Contraceptive CHOICE
project in the US has shown that the use of LARC, including IUC, can
be increased via good contraceptive counseling. When women
were given structured counseling on the beneﬁts and risks of all
reversible methods, including LARC, and then given a choice of any
method provided free of charge, 75% of women chose LARC (IUC or
implant) and 58% chose IUC (levonorgestrel intrauterine system
[LNG-IUS] or copper intrauterine device) [4]. Additionally, women
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the highest user satisfaction [6]. Furthermore, the unintended
pregnancy rate among LARC users was 10-fold lower than among
women using short-acting hormonal methods [7] and the induced
abortion rate in the CHOICE cohort (which included a high
proportion of LARC users) was substantially lower than the
regional (St. Louis) abortion rate [4].
Despite the fact that international and national guidelines
support the use of IUC in a wide range of women, regardless of
age and parity status [8–12], various barriers and misperceptions
persist that limit its more widespread use [13]. For example, a
cross sectional survey of obstetricians and gynecologists in the
St. Louis region demonstrated that several misperceptions persist
concerning the safety of IUC, particularly the misperception that
IUC causes pelvic inﬂammatory disease [14]. The extent to which
these barriers and misconceptions persist in different countries
may explain the wide variation in utilization rates between
countries [15]. The wider acceptance and use of the LNG-IUS in
Scandinavia may be because the initial studies with the LNG-IUS
were conducted in Finland.
We conducted an online survey to gain a greater understanding
of the various barriers and misperceptions about IUC that persist
among providers of contraception, especially regarding use in
nulliparous women, and to identify initiatives to improve
providers’ knowledge of IUC and eliminate barriers to use so that
IUC methods are included in contraceptive counseling. The results
from the overall cohort (providers from 15 countries across
4 regions) have been published [16]. Here, we report a subgroup
analysis of the responses from providers of contraception in
Europe and Canada.
Materials and methods
An online survey of providers of contraception in Canada,
France, Germany, Ireland, The Netherlands, Russia, Sweden, Turkey
and the UK was conducted between February and March 2012. The
questionnaire was developed by the INTRA (Intrauterine Contra-
ception for Nulliparous Women: Translating Research into Action)
group, an international advisory group of 10 physicians. The
logistics of distributing and administering the survey were
undertaken by GfK, a global market research organization, with
funding from Bayer HealthCare. The questionnaire was translated
into the languages of each of the countries by native speakers; each
local language version was tested for comprehension before roll-
out. In each country, HCPs were identiﬁed from existing nursing
and medical market research panels of healthcare professionals
who had expressed an interest in participating in research. These
panels were created by the market research company ‘World One’.
Individuals were selected from these panels by random sampling;
those selected were sent an email invite to participate. HCPs who
were willing to participate answered screening questions, which
sought to exclude individuals with a relationship to any
pharmaceutical company and ensure that respondents who went
on to complete the survey saw at least 20 women per month for
contraceptive counseling. Additionally, screening ensured that
respondents were one of the following types of HCP: an
obstetrician–gynecologist (OB–GYN), a general practitioner (GP)
or a family planning clinician (FPC; a physician, midwife or nurse
with a speciﬁc women’s health qualiﬁcation).
The types of HCP who provide contraceptive services vary
between countries. For example, in Germany, contraceptive
services are provided exclusively by gynecologists, whereas in
other countries, a wider range of HCPs are active in the provision of
contraception. Therefore, it was important that, for each country,
the respondent samples were representative of the types of HCP
who provide contraception services. The relative percentages ofdifferent types of HCP who provide contraception in individual
countries were determined through collaborative discussions
between the INTRA group physicians, expert physicians from
the relevant countries and representatives from Bayer HealthCare
in individual countries. Accordingly, recruitment quotas for
different HCP types were set for individual countries (Table 2
footnote). Respondents fulﬁlling the screening criteria progressed
to a structured questionnaire (Table 1).
Results
Response rates
Response rates in individual countries were as follows: Canada,
15%; Germany, 19%; France, 21%; UK, 29%; Russia, 28%; Sweden,
15%; The Netherlands, 13%; Turkey, 20%; Ireland, 15%. These
percentages reﬂect the number of HCPs who responded to the email
invite, passed screening and then went on to complete the main
questionnaire, with the total number of HCPs sent an email invite as
the denominator.
Respondent characteristics
A total of 1103 respondents completed the survey, of which
633 were OB–GYNs, 335 were GPs and 135 were FPCs. Further
details are shown in Tables 2 and 3. The mean number of devices
inserted per month ranged from 7.7 for respondents in Russia to
23.4 for respondents in France.
Barriers to use of intrauterine contraception in general
Respondents were asked to report their three main barriers to
considering IUC for women in general (i.e. respondents were asked
to report their own barriers, not what they thought were the main
barriers for other HCPs in their country) (Fig. 1). The two most
frequently reported barriers, by country, were as follows:
nulliparity and concerns about pelvic inﬂammatory disease
(PID) in Canada, France, Russia and Turkey; disruption of normal
menstruation and concerns about insertion-related pain in
Sweden; nulliparity and ﬁnancial cost in Germany; concerns
about insertion difﬁculty and nulliparity in the UK and Ireland;
concerns about insertion-related pain and nulliparity in The
Netherlands (Fig. 1).
The impact of IUC on menstruation was frequently reported as a
barrier by respondents in Turkey and Sweden, but was less
frequently of concern in Canada, The Netherlands and Ireland
(Fig. 1). In Russia, concerns about nulliparity and PID were
particularly prevalent whereas concerns about insertion-related
pain and insertion difﬁculty were less prevalent in Russia than in
other countries. In addition, concern about non-monogamy was
more prevalent in Russia than in other countries (Fig. 1).
Financial cost was reported as a barrier most frequently by
respondents in Germany and Canada (35% and 32%, respectively);
of the countries represented in the survey, these two have the
lowest IUC utilization rates (Table 2).
The perception that ‘women don’t like it [IUC]’ was reported
most frequently by HCPs in Sweden, UK, Germany, Canada, Ireland
and The Netherlands and least frequently by HCPs in France, Russia
and Turkey (Fig. 1).
Barriers to use of intrauterine contraception in nulliparous women
Respondents were asked to report their three main barriers to
considering IUC for a nulliparous woman requesting contraception
(Fig. 2). Concerns about insertion difﬁculty and insertion-related
pain were the two most frequent barriers in all countries except
Table 1
Survey questions.
Collection of demographic and clinical practice data on respondents
Question Multiple-choice response options
1. What type of healthcare professional are you? Gynecologist; GP; family planning clinician
2. How many women do you see in a typical month about contraception? 20; 21–30; 31–40; 41–50; 51–100; 101–150; 151–200; >200
3. How many years is it since you began to provide independent, unsupervised
contraception advice and services?
0–10 years; 11–20 years; >20 years
4. What role do you play in providing IUC? None; I refer to a colleague for insertion; I train/supervise
insertion only; I insert AND train/supervise; I insert myself
5. In a typical month, how many IUDs (copper IUD and LNG-IUS) do you personally insert? 1–5; 6–10; 11–15; 16–20; 21–30; 31–40; >40
Examining the barriers to considering IUC for a woman requesting contraception
Question Response
1. What are the three main barriers for you as a physician when considering IUC in general? Respondents to select their top three options from a list
2. What are the three main barriers for you as a physician when considering IUC in
nulliparous
women?
Respondents to select their top three options from a list
Examining respondents’ perceptions on the efﬁcacy and risks of IUC
Question Multiple-choice response options
1. Thinking about the contraceptive efﬁcacy of IUC: compared with parous women,
the efﬁcacy of IUC in nulliparous women is
Much less; a little less; the same; a little better; much better
2. What risk do you think a nulliparous woman with IUC has of PID and subsequent
infertility compared with a woman NOT using IUC?
Much higher risk; a little higher risk; the same risk; a little lower
risk; much lower risk
3. What risk do you think a nulliparous woman with IUC has compared to a parous
woman with IUC with regard to uterine perforation?
Much higher risk; a little higher risk; the same risk; a little lower
risk; much lower risk
4. What risk do you think a nulliparous woman with IUC has compared with a parous
woman with IUC with regard to expulsion of the device/system?
Much higher risk; a little higher risk; the same risk; a little lower
risk; much lower risk
Examining respondents’ perceptions of the ease and pain of insertion
Question Multiple-choice response options
1. Thinking about the ease of placing/inserting IUC: how would you describe insertion
in a nulliparous woman compared with a parous woman?
Much more difﬁcult; a little more difﬁcult; the same; a little
easier; much easier
2. Thinking about the experience of the woman at insertion: when comparing the
experience of a nulliparous woman with a parous woman do you believe the
nulliparous woman will experience
Much more pain; a little more pain; the same amount of pain; a
little less pain; much less pain
Examining respondents’ attitudes toward proactive inclusion of IUC in contraceptive counseling
Question Response options (respondents could ‘tick’ as many options as
they desired)
1. Please indicate with which of the following types and ages of
women you would discuss IUC?
Nulliparous women: <18 years; 18–29 years; 30–39 years; 40
years; none of these women
Parous women: <18 years; 18–29 years; 30–39 years; 40 years;
none of these women
Examining respondents’ knowledge of medical eligibility criteria
Question Multiple-choice response options
1. Off the top of your head, how do the WHO MEC categorize the
use of IUC in nulliparous women?
Unrestricted (MEC 1); the beneﬁts outweigh the risks (MEC 2); the
risks outweigh the beneﬁts (MEC 3); contraindicated (MEC 4); I
don’t know
Examining respondents’ opinions on what would increase their
knowledge and conﬁdence in IUC for nulliparous women
Question Response
1. What would best increase your knowledge and conﬁdence in using IUC in nulliparous
women?
Respondents to select their top three options from a list
2. What type of information would you require the most to increase your knowledge
and conﬁdence in using IUC in nulliparous women?
Respondents to select their top three options from a list
GP, general practitioner; IUC, intrauterine contraception; IUD, intrauterine device; LNG-IUS, levonorgestrel intrauterine system; MEC, Medical Eligibility Criteria; PID, pelvic
inﬂammatory disease; WHO, World Health Organization.
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two most frequent barriers were concerns about insertion
difﬁculty and PID, whereas in Russia and Turkey, the two most
frequent barriers were concerns about PID and concerns about
infertility.
In Sweden, disruption of menstruation was a more frequent
barrier and concern about PID was a less frequent barrier,
compared with in other countries. The age of the woman was a
more frequent barrier in The Netherlands than in the other
countries. Concern about non-monogamy was a more frequentbarrier in Russia than in other countries. Concern about ectopic
pregnancy was a more frequent barrier in France, Russia and
Turkey than in other countries.
Perceptions of intrauterine contraception in nulliparous women:
Efﬁcacy, safety, ease of insertion and insertion-related pain
The percentage of respondents who believed that IUC is equally
effective in nulliparous and parous women ranged from 83% in The
Netherlands to 95% in Sweden.
Table 3
Respondents’ professional characteristics.
Canada
(n = 100)
Germany
(n = 150)
France
(n = 150)
UK
(n = 150)
Russia
(n = 150)
Sweden
(n = 100)
The Netherlands
(n = 100)
Turkey
(n = 100)
Ireland
(n = 103)
Median number of patients/month seen for contraception 50 200 120 50 48 40 30 50 30
Mean years of experience in contraception 18.9 14.5 22.7 15.3 13.1 16.3 18.5 13.4 15.8
Role in provision of IUC (%)
Insert IUC themselves 46 95 83 33 87 62 77 80 43
Insert + train/supervise 9 3 11 1 7 23 8 9 7
Train/supervise only 0 1 1 1 1 0 0 4 0
Refer to colleague for insertion 45 1 4 64 4 14 14 6 50
None 0 0 1 1 1 1 1 1 0
Mean number of devices inserted/month* 9.2 8.1 23.4 9.3 7.7 9.3 8.8 18.0 10.7
HCP, healthcare provider; IUC, intrauterine contraception.
* Sub-sample of HCPs who reported that they insert IUC themselves: Canada, n = 55; Germany, n = 147; France, n = 141; UK, n = 52; Russia, n = 141; Sweden, n = 85; The
Netherlands, n = 85; Turkey, n = 89; Ireland, n = 51.
Table 2
Sample size and composition.
Country Respondents by medical specialty Total (n) Proportion of women aged 15–49 years
who use IUC (%) [15]
General practitioners
(GPs) (n)
Family planning
clinicians* (FPCs) (n)
Obstetrician–gynecologists
(OB–GYNs) (n)
Canada 75 – 25 100 1.0
Germany – – 150 150 5.9
France – 25 125 150 18.9
UK 110 40 – 150 10.0
Russia – – 150 150 20.4
Sweden – 70 30 100 16.2
The Netherlands 70 – 30 100 8.0
Turkey – – 100 100 16.9
Ireland 80 – 23 103 8.4
Total 335 135 633 1103
Recruitment quotas for different HCP types were set for individual countries as follows: Canada, 75% GPs, 25% OB-GYNs; Germany, 100% OB–GYNs; France, 15% FPCs, 85% OB–
GYNs; UK, 75% GPs, 25% FPCs; Russia, 100% OB–GYNs; Sweden, 70% FPCs, 30% OB–GYNs; The Netherlands, 70% GPs, 30% OB–GYNs; Turkey, 100% OB–GYNs; Ireland, 80% GPs,
20% OB–GYNs.
Canadian and European healthcare providers (HCPs) were surveyed together because the Canadian healthcare system is similar to the healthcare systems in European
countries.
* The type of healthcare provider classed as a ‘family planning clinician’ varied between countries as follows: France, physician working in family planning; UK, family
planning nurse; Sweden, midwife. IUC, intrauterine contraception; UK, United Kingdom.
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or ‘a little higher’) in nulliparous IUC users than in women not
using IUC was most prevalent in Russia (88%) and France (73%)
and least prevalent in Sweden (38%) (Table 4). The perception
that nulliparous women using IUC are at ‘much higher’ risk of
PID/infertility than women not using IUC was most prevalent in
Russia (44%) and France (13%) and was least prevalent in Sweden
(0%) and The Netherlands (1%).
The belief that the risk of uterine perforation is higher (‘much
higher’ or ‘a little higher’) in nulliparous than parous women was
most prevalent in Germany (50%) and least prevalent in Sweden
(33%) (Table 4).
Perceptions of expulsion risk in nulliparous women compared
with parous women were mixed. The belief that the risk of
expulsion is higher (‘much higher’ or ‘a little higher’) in
nulliparous women than parous women was most prevalent in
France (48%) and least prevalent in Turkey (16%). Conversely, the
belief that the risk of expulsion is lower (‘much lower’ or ‘a little
lower’) in nulliparous than parous women was most prevalent in
Turkey (56%) and least prevalent in Sweden (18%) and France
(18%) (Table 4).
The perception that intrauterine contraceptives are ‘much more
difﬁcult’ to insert in nulliparous than parous women was most and
least prevalent in Ireland (43%) and Sweden (2%), respectively(Table 5). The perception that the insertion of intrauterine
contraceptives is ‘much more painful’ in nulliparous than parous
women was most and least prevalent in Russia (35%) and Sweden
(10%), respectively.
Contraceptive counseling
In most of the countries, respondents were much more likely to
proactively include IUC in contraceptive counseling for a parous
woman than for a nulliparous woman. The percentage of
respondents who reported that they never proactively include
IUC in contraceptive counseling for nulliparous women ranged
from 4% in The Netherlands to 59% in Russia (Table 6).
Respondents’ knowledge of the World Health Organization Medical
Eligibility Criteria for intrauterine contraception
The percentages of respondents who correctly identiﬁed
nulliparity as category 2 (beneﬁts outweigh the risks) were
highest in The Netherlands (61%) and France (59%) and lowest in
Russia (30%) (Fig. 3). Nulliparity was incorrectly identiﬁed as
category 3 (risks outweigh the beneﬁts) or category 4 (contra-
indicated) more frequently by respondents in Russia than by
respondents in other countries.
Fig. 2. Barriers to considering intrauterine contraception for nulliparous women. The bars show the percentage of respondents that reported each barrier as one of their top
three barriers to considering intrauterine contraception for nulliparous women. Respondents were asked to report their barriers to considering intrauterine contraception for
nulliparous women without differentiating between the type of device. This included reporting of ‘disruption of normal menstruation’ as a barrier, even though hormonal and
copper devices are associated with different bleeding proﬁles. MoA, mode of action; PID, pelvic inﬂammatory disease.
Fig. 1. Barriers to considering intrauterine contraception for women in general. The bars show the percentage of respondents that reported each barrier as one of their top
three barriers to considering intrauterine contraception for women in general. Respondents were asked to report their barriers to considering intrauterine contraception for
women in general without differentiating between the type of device. This included reporting of ‘disruption of normal menstruation’ as a barrier, even though hormonal and
copper devices are associated with different bleeding proﬁles. MoA, mode of action; PID, pelvic inﬂammatory disease.
K.J. Buhling et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 183 (2014) 146–154150
Table 5
Respondents’ perceptions of the ease and pain of intrauterine contraceptive insertion in nulliparous women compared with parous women.
Ease of placement Pain associated with placement
Number of
respondents*
A little more
difﬁcult (%)
Much more difﬁcult (%) Number of respondents A little more painful (%) Much more
painful (%)
Canada 94 62 27 100 68 19
Germany 148 63 29 150 64 25
France 143 69 19 150 53 26
United Kingdom 134 60 30 150 70 11
Russia 88 66 24 150 47 35
Sweden 92 83 2 100 67 10
The Netherlands 98 76 15 100 58 22
Turkey 92 75 20 100 69 20
Ireland 83 51 43 103 58 32
* Excluded respondents who reported that they do not insert intrauterine contraceptives in nulliparous women.
Table 4
Respondents’ perceptions of the risks of PID/infertility, uterine perforation and expulsion associated with use of IUC in nulliparous women. IUC, intrauterine contraception;
PID, pelvic inﬂammatory disease.
Country Respondents (%)
Risk of PID/infertility is
higher than in non-IUC users
Higher risk of uterine perforation
vs parous women
Higher risk of expulsion
vs parous women
Lower risk of expulsion
vs parous women
Canada (n = 100) 61 38 34 30
Germany (n = 150) 61 50 34 28
France (n = 150) 73 44 48 18
United Kingdom (n = 150) 53 44 29 25
Russia (n = 150) 88 46 31 42
Sweden (n = 100) 38 33 40 18
The Netherlands (n = 100) 57 45 35 23
Turkey (n = 100) 67 42 16 56
Ireland (n = 103) 58 42 37 35
Higher risk = a little higher or much higher risk; lower risk = a little lower or much lower risk.
IUC, intrauterine contraception; PID, pelvic inﬂammatory disease.
Table 6
Percentage of respondents who reported never including IUC in contraceptive counseling for nulliparous women and for parous women, by country.
Country Respondents (%)
Never proactively include IUC in counseling for a nulliparous
woman, regardless of her age
Never proactively include IUC in counseling for a parous
woman, regardless of her age
Canada (n = 100) 13 0
Germany (n = 150) 9 0
France (n = 150) 19 0
United Kingdom (n = 150) 15 1
Russia (n = 150) 59 1
Sweden (n = 100) 6 0
The Netherlands (n = 100) 4 0
Turkey (n = 100) 37 0
Ireland (n = 103) 27 1
IUC, intrauterine contraception.
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conﬁdence in intrauterine contraception for nulliparous women
Respondents were asked to select three initiatives that would
increase their knowledge and conﬁdence in IUC for nulliparous
women. The most frequent answers, by country, are summarized
in Table 7.
Respondents were asked to select three types of information
they would require to increase their knowledge and conﬁdence in
using IUC in nulliparous women. The results are summarized in
Fig. 4.
Comment
This survey conﬁrms that various barriers and misperceptions
persist among HCPs across Europe and Canada, which may explain
the low IUC utilization rates in some countries. Overall, the main
barriers to HCPs considering IUC for women in general were‘nulliparity’ and ‘concerns about PID’, whereas the main barriers
when considering IUC speciﬁcally for nulliparous women were
concerns about PID and concerns about difﬁculty and pain
associated with insertion.
Many of the barriers to use of IUC and many of the perceptions
of IUC reported by the HCPs surveyed, particularly those pertaining
to use in nulliparous women, are not evidence-based. Perhaps of
greatest concern is that the misperception that IUC causes PID and
infertility persists among many of the HCPs surveyed, despite
strong evidence that PID is caused by sexually transmitted
infections (STIs), particularly chlamydia, not the devices them-
selves [11,13,17]. Young women and non-monogamous women
generally have a higher STI risk [18,19]. However, this should not
be a reason to withhold IUC as an option from these women;
instead HCPs should counsel them to use condoms in addition to
IUC.
HCPs’ concerns that IUC is ‘much more difﬁcult’ and ‘much
more painful’ to insert in nulliparous women than parous women
Fig. 3. Respondents’ knowledge of the WHO MEC for IUC. The bars respondents’ answers to the following question: How do the WHO MEC categorize the use of IUC in nulliparous
women?. The bar for Ireland does not add up to 100% because of rounding. IUC, intrauterine contraception; MEC, Medical Eligibility Criteria; UK, United Kingdom; WHO, World
Health Organization.
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more difﬁcult and a little more painful in nulliparous than parous
women, IUC is inserted with ease in most nulliparous women
[20–22] and with no more than ‘moderate’ pain’ [20].
HCP’s concerns regarding risks of uterine perforation, device
expulsion and ectopic pregnancy are also misplaced; the risks of
perforation and expulsion are low in both nulliparous and parous
women [11,20,23]. The absolute incidence of ectopic pregnancy inTable 7
The most frequently reported initiatives when respondents were asked to select
three initiatives that would increase their knowledge and conﬁdence in IUC for
nulliparous women, by country.
Country Most frequently reported initiatives (respon-
dents, %)
Canada (n = 100) More presentations at local meetings (44%)
Germany (n = 150) More articles in professional magazines/
newspapers (non-peer reviewed periodicals)
(41%)
France (n = 150) More social acceptance of IUC (30%)
More presentations at national conferences
(29%)
Articles in professional magazines/
newspapers (non-peer reviewed periodicals)
(29%)
United Kingdom (n = 150) More presentations at local meetings (49%)
Speciﬁc practical training on insertion (47%)
Russia (n = 150) More articles in professional magazines/
newspapers (non-peer reviewed periodicals)
(52%)
Sweden (n = 100) More presentations at local meetings (36%)
Easily accessible data (36%)
The Netherlands (n = 100) More articles in professional magazines/
newspapers (non-peer reviewed periodicals)
(40%)
Turkey (n = 100) More presentations at national conferences
(37%)
More presentations at international
conferences (38%)
Ireland (n = 103) More presentations at local meetings (58%)IUC users is also very low and similar to the background ectopic
pregnancy rate [24,25]. Furthermore, there is no evidence that risk
of ectopic pregnancy is inﬂuenced by parity [26,27].
The survey revealed that HCPs across Europe and Canada are less
likely to proactively include IUC in contraceptive counseling for a
nulliparous woman than for a parous woman, regardless of her age.
This is despite MEC and guidelines that support use of IUC in a wide
range of women, regardless of parity or age [8–12]. This could reﬂect
lack of awareness and understanding of MEC and guidelines; indeed
our results indicated that HCPs’ knowledge of the WHO MEC for IUC
is consistently poor across Europe and Canada.
Study limitations
The following limitations of the survey are acknowledged. First,
respondents completed the survey online and unassisted, there-
fore some respondents may not have fully understood certain
questions, for example, respondents were asked to answer
questions on barriers to IUC use from their own perspective, but
may have answered based on what they perceive other HCPs’
barriers to be or what they perceive women’s barriers to be.
Second, many of the questions required respondents to select their
answers from a list (albeit an extensive one), which, may have
inﬂuenced the results. Third, when respondents reported their
three main barriers to considering contraception for women in
general and speciﬁcally for nulliparous women, ‘concern about
PID’ and ‘concern about infertility’ were included separately in
the list of options; because PID and infertility are related, it is
possible that these two options split the vote: some respondents
may have chosen either PID or infertility, but not both. Fourth,
when respondents reported ‘disruption of normal menstruation’ as
a barrier to considering IUC, it is impossible to know whether their
concern was about the bleeding associated with copper IUDs or the
bleeding associated with the LNG-IUS. Fifth, data on the number of
distinct work places were not collected, therefore we do not know
whether multiple respondents were from the same institution and
Fig. 4. Information required for increasing knowledge and conﬁdence in use of IUC in nulliparous women. The bars show the percentage of respondents that reported each
type of information as one of their top three information requirements. IUC, intrauterine contraception; PID, pelvic inﬂammatory disease.
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owing to random sampling, it is unlikely that this was the case.
In addition, the recruitment of relatively small samples
(between 100 and 150 respondents per country), and sampling
from panels of healthcare providers who had elected to participate
in a medical research surveys carries a risk of selection bias. To
minimize this risk, quotas for different HCP types were set in each
country to ensure recruitment of representative samples.
Study strengths
The strengths of this survey included the following: it was
designed for simultaneous administration in different countries;Table 8
Intrauterine contraception: misperceptions vs scientiﬁc evidence.
Misperception Scientiﬁc e
IUC is not suitable for nulliparous women The eviden
women re
category 2
IUC causes pelvic inﬂammatory disease PID is caus
There is a s
related to 
transferred
transport i
insertion p
[11,17,29]
IUC increases the risk of ectopic pregnancy The overal
of ectopic 
It is difﬁcult to insert IUC in a nulliparous woman In studies,
investigato
Insertion of IUC is too painful for a nulliparous woman In studies,
‘moderate
The risk of uterine perforation is high in nulliparous women The incide
Nulliparous women are likely to expel their device The incide
IUC, intrauterine contraception.the questionnaire was translated into local languages and tested
locally for comprehension before roll out; only healthcare
providers who were active in the provision of contraceptive
counseling were surveyed; and in each country different types of
healthcare provider were recruited in ratios that reﬂected the
types of provider who provide contraceptive counseling.
Other surveys of European providers
The methods of contraception that HCPs and their partners use
themselves and the methods of contraception that they recom-
mend to their patients has been studied in a multinational online
survey [28]. Among 1001 male and female HCPs involved invidence
ce-based WHO MEC for contraceptive use support use of IUC in a wide range of
gardless of age or parity. For both the LNG-IUS and the copper IUD nulliparity is
 (the beneﬁts outweigh the risks) [8]
ed by sexually transmitted infections (STIs), mainly chlamydia and gonorrhea.
lightly increased incidence of PID in the ﬁrst 3 weeks after placement of IUC. This is
the insertion procedure, during which a pre-existing infection, including STI, is
 into the uterus when the sterile device may become a vehicle for microbial
n the upper genital tract. To avoid transferring pre-existing infections during the
rocedure, consider screening women considered to be at high risk of STIs
l pregnancy rate among IUC users in very low [3], therefore the absolute incidence
pregnancy is also low and similar to the background ectopic pregnancy rate [25]
 72–85% of IUC insertions in nulliparous women were considered to be ‘easy’ by
rs [20–22]
 79–85% of nulliparous women rated their insertion-related pain as no more than
’ [20,21,30]
nce of uterine perforation is low regardless of parity [20,31–34]
nce of expulsion is low regardless of parity [11,20,23]
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commonly used personally was the LNG-IUS. Regarding the
methods that HCPs recommended to their patients, the LNG-IUS
was the second most frequently recommended method for spacers
and the most frequently recommended method for women who
have completed their family. The HCP being female, aged 36–45
years of age and being an OB–GYN were factors associated with a
higher likelihood of recommending the LNG-IUS as second choice
for spacers. The HCP being female, aged 46–55 years, an OB–GYN,
and an LNG-IUS user were factors associated with a higher
likelihood of recommending the LNG-IUS as ﬁrst choice for women
who have completed their family.
Conclusion
IUC needs to be recognized as a suitable option for nulliparous
women and be proactively included as an option in their
contraceptive counseling. Further education on the scientiﬁc
evidence regarding IUC is needed, especially regarding pelvic
inﬂammatory disease. Knowledge of the WHO MEC also needs to
be improved. In addition, HCPs’ perceptions of the insertion
procedure highlight the need (a) for practical insertion training to
be more widely available and (b) for further studies on pain
management to be conducted to increase HCPs’ comfort in
performing IUC insertions. Education on the evidence presented
in Table 8 may help to overcome HCPs misperceptions so that they
more frequently include IUC as an option during contraceptive
counseling, which in turn may lead to more widespread use of IUC
and a reduction in unintended pregnancy rates.
Condensation
This article emphasizes on Healthcare providers’ gaps in their
knowledge regarding intrauterine contraception by presenting the
results of a huge survey in Europe and Canada.
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